Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association.
Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association.
复制标题
DOI：
10.1161/hcg.0000000000000032
复制
发表时间：
2017-04
期刊：
影响因子：
--
通讯作者：
American Heart Association Council on Functional Genomics and Translational Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council
中科院分区：
文献类型：
--
作者：
Cheng S;Shah SH;Corwin EJ;Fiehn O;Fitzgerald RL;Gerszten RE;Illig T;Rhee EP;Srinivas PR;Wang TJ;Jain M;American Heart Association Council on Functional Genomics and Translational Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Stroke Council
通过测量不同生物系统中数千种小分子代谢物，代谢组学现在为了解导致心血管疾病等复杂人类疾病的因素提供了新的见解。靶向代谢组学方法已经确定了心血管疾病风险的新分子标记和代谢组学特征（包括支链氨基酸、精选不饱和脂类和三甲胺- n -氧化物），从而有效地将饮食摄入和微生物群等不同暴露与心脏代谢特征联系起来。随着代谢组学技术的不断发展，复杂系统中小分子代谢物分析的深度和广度继续快速发展，以及不断发现的前景。代谢组学领域目前面临的挑战包括代谢组学方法的规模吞吐量和技术能力，处理大规模代谢组学数据的生物信息学和化学信息学工具，阐明新型代谢物的生化结构和功能的方法，以及确定与心血管疾病结局相关的代谢物的真正临床相关性的策略。在应对这些挑战方面取得的进展将使代谢组学有潜力实质性地影响心血管医学的诊断和治疗。
Through the measure of thousands of small-molecule metabolites in diverse biological systems, metabolomics now offers the potential for new insights into the factors that contribute to complex human diseases such as cardiovascular disease. Targeted metabolomics methods have already identified new molecular markers and metabolomic signatures of cardiovascular disease risk (including branched-chain amino acids, select unsaturated lipid species, and trimethylamine-N-oxide), thus in effect linking diverse exposures such as those from dietary intake and the microbiota with cardiometabolic traits. As technologies for metabolomics continue to evolve, the depth and breadth of small-molecule metabolite profiling in complex systems continue to advance rapidly, along with prospects for ongoing discovery. Current challenges facing the field of metabolomics include scaling throughput and technical capacity for metabolomics approaches, bioinformatic and chemoinformatic tools for handling large-scale metabolomics data, methods for elucidating the biochemical structure and function of novel metabolites, and strategies for determining the true clinical relevance of metabolites observed in association with cardiovascular disease outcomes. Progress made in addressing these challenges will allow metabolomics the potential to substantially affect diagnostics and therapeutics in cardiovascular medicine.